Are anidulafungin or voriconazole released from polymethylmethacrylate in vitro?

Mark S. Rouse, Andras Heijink, James M. Steckelberg, Robin Patel

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Abstract

Background: Depot delivery of antimicrobial agents is used for treatment and prevention of bacterial orthopaedic infections; there is little information regarding newer antifungal agents and their potential use in polymethylmethacrylate (PMMA) depot delivery. Questions/purposes: We determined the percent of anidulafungin or voriconazole present after polymerization in PMMA beads loaded with anidulafungin or voriconazole, and we assessed elution of anidulafungin or voriconazole from beads loaded with anidulafungin or voriconazole. Materials and Methods: Beads containing 7.5% anidulafungin or voriconazole were pulverized and incubated in Kreb's ringer buffer for 48 hours; the buffer was assayed for anidulafungin or voriconazole concentration. The in vitro release of anidulafungin and voriconazole from PMMA beads loaded with 7.5% anidulafungin or voriconazole was determined in triplicate in a continuous flow chamber. Results: 0.7% of anidulafungin and 5.6% of voriconazole loaded in the beads were detected after polymerization. No anidulafungin was detected in the elution studies. The mean peak voriconazole concentration in the elution studies was 0.9 μg/mL. Conclusions: Anidulafungin may not be suitable for depot delivery in PMMA.

Original languageEnglish (US)
Pages (from-to)1466-1469
Number of pages4
JournalClinical orthopaedics and related research
Volume469
Issue number5
DOIs
StatePublished - May 2011

ASJC Scopus subject areas

  • Surgery
  • Orthopedics and Sports Medicine

Fingerprint Dive into the research topics of 'Are anidulafungin or voriconazole released from polymethylmethacrylate in vitro?'. Together they form a unique fingerprint.

Cite this